Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Seminoma 1 Prostate Cancer Metastatic 1 Ovarian Neoplasms 1 Neutropenia 1 Neoplasms 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Endodermal Sinus Tumor 1 Central Nervous System Neoplasms 1 Castrate Resistant Prostate Cancer 1

Interventions

Radiosurgery 5 Androgen Antagonists 4 enzalutamide 2 Prednisone 2 Docetaxel 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 olaparib 1 gallium 68 PSMA-11 1 darolutamide 1 cabazitaxel 1 apalutamide 1 XRP6258 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hematologic Tests 1 Granulocyte Colony-Stimulating Factor 1 Gonadotropin-Releasing Hormone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostate Cancer Metastatic × Lenograstim × Clear all

NCT02961257 2022-05-12

CABASTY

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Phase 3 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡